Compare Piramal Healthcare with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs ASTRAZENECA PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES ASTRAZENECA PHARMA PIRAMAL ENTERPRISES/
ASTRAZENECA PHARMA
 
P/E (TTM) x 18.4 73.6 25.0% View Chart
P/BV x 1.2 20.7 5.6% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 PIRAMAL ENTERPRISES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
ASTRAZENECA PHARMA
Mar-18
PIRAMAL ENTERPRISES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3031,278 258.4%   
Low Rs1,797883 203.6%   
Sales per share (Unadj.) Rs716.5228.4 313.7%  
Earnings per share (Unadj.) Rs79.710.4 769.0%  
Cash flow per share (Unadj.) Rs107.916.3 663.6%  
Dividends per share (Unadj.) Rs28.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs1,477.598.8 1,495.9%  
Shares outstanding (eoy) m184.4525.00 737.8%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.64.7 75.2%   
Avg P/E ratio x32.0104.2 30.7%  
P/CF ratio (eoy) x23.666.4 35.6%  
Price / Book Value ratio x1.710.9 15.8%  
Dividend payout %35.10-   
Avg Mkt Cap Rs m470,29227,008 1,741.3%   
No. of employees `0007.81.4 576.7%   
Total wages/salary Rs m22,5041,535 1,465.7%   
Avg. sales/employee Rs Th16,899.44,210.9 401.3%   
Avg. wages/employee Rs Th2,877.71,132.2 254.2%   
Avg. net profit/employee Rs Th1,879.9191.1 983.9%   
INCOME DATA
Net Sales Rs m132,1535,710 2,314.4%  
Other income Rs m3,128123 2,553.5%   
Total revenues Rs m135,2815,833 2,319.4%   
Gross profit Rs m66,290463 14,320.5%  
Depreciation Rs m5,202147 3,528.8%   
Interest Rs m44,0970-   
Profit before tax Rs m20,119438 4,593.3%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,611179 4,813.5%   
Profit after tax Rs m14,701259 5,673.9%  
Gross profit margin %50.28.1 618.8%  
Effective tax rate %42.840.8 104.8%   
Net profit margin %11.14.5 245.2%  
BALANCE SHEET DATA
Current assets Rs m122,7423,209 3,824.7%   
Current liabilities Rs m310,8102,070 15,018.6%   
Net working cap to sales %-142.320.0 -713.0%  
Current ratio x0.41.6 25.5%  
Inventory Days Days2372 31.9%  
Debtors Days Days3935 111.2%  
Net fixed assets Rs m116,904790 14,792.4%   
Share capital Rs m36950 737.8%   
"Free" reserves Rs m272,1612,419 11,249.6%   
Net worth Rs m272,5302,469 11,036.7%   
Long term debt Rs m270,1960-   
Total assets Rs m856,2614,605 18,592.5%  
Interest coverage x1.5NM-  
Debt to equity ratio x1.00-  
Sales to assets ratio x0.21.2 12.4%   
Return on assets %6.95.6 122.1%  
Return on equity %5.410.5 51.4%  
Return on capital %12.417.7 70.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,200300 5,074.4%   
Fx outflow Rs m4,8892,015 242.6%   
Net fx Rs m10,312-1,715 -601.1%   
CASH FLOW
From Operations Rs m-115,97588 -131,939.2%  
From Investments Rs m-8,265-94 8,830.2%  
From Financial Activity Rs m107,525NA-  
Net Cashflow Rs m-16,650-6 292,108.8%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.0 0.3 1,333.3%  
FIIs % 26.6 15.7 169.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 9.1 181.3%  
Shareholders   93,274 12,856 725.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  UNICHEM LAB  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Sep 20, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS